Oxford Symposia - 3rd Annual


Antisense & Therapeutic Nucleic Acids

10 April 2017, St Hilda's College, Oxford, UK

Twitter: @LPMHealthcare, #OligoOx17

Posters and guidelines

Guidelines for poster preparation

Please prepare your poster in A1 portrait format (59cm wide x 84cm long). Do not laminate your poster, or use heavy material to print your poster. Further information about poster sizes can be found on the following link:

Posters larger than A1 will only be displayed subject to the availability of space.

Maximum capacity 10 A1 potrait posters

Please ensure you have appropriate permissions for the publication of your abstract from the original copyright holders. Should you wish your abstract not to be published, please notify us in writing at the time of abstract submission.

>>Where can I print my poster in Oxford?

Posters will be displayed for the full duration of the symposium.

Accepted posters

(Presenters in Bold)

If your abstract has been accepted for presentation but it does not appear in the list below, please let us know as soon as possible by email on

From DNA aptamer structure to splitting for use in DNA nanotweezers

Yee-Wai Cheung, Simon Chi-Chin Shiu, Wai-Chung Wong, Marco SL Tang, Roderick M Dirkzwager, Shaolin Liang, Andrew B Kinghorn, Lewis A Fraser and Julian A Tanner

School of Biomedical Sciences, The University of Hong Kong, Laboratory Block, 21 Sassoon Road, Hong Kong

DNA tweezers are DNA nanostructures which dynamically open and close by annealing of complementary nucleic acid sequences. DNA tweezers which respond to protein molecular recognition have not yet been developed but nucleic acid aptamers provide a useful oligomeric interface between DNA nanostructure and sensing of other molecular species. Our previous studies identified a DNA aptamer targeted Plasmodium falciparum lactate dehydrogenase (PfLDH) and the X-ray crystal structure of this complex was further elucidated…

Novel N-(sulfonyl)-phosphoramidate DNA analogues as potential antisense agents

Boris P Chelobanov1,2, Alesya A Fokinа1, Ekaterina A Burakovа1, Dmitry A Stetsenkо1,2

1Institute of Chemical Biology and Fundamental Medicine SB RAS, 8 Lavrentiev Avenue, Novosibirsk, Russia
2Novosibirsk State University, 2 Pirogov Street, Novosibirsk, Russia

DNA derivatives with modified internucleotide phosphate groups such as phosphorothioates are used in chemical biology as nuclease-resistant oligonucleotide analogues and in medicine as antisense therapeutics. In this type belong also oligonucleotides with one or a few N-(sulfonyl)-phosphoramidate groups, which have been shown to form stable duplexes with DNA. Recently, novel N-(sulfonyl)-phosphoramidate oligodeoxynucleotides were obtained in our laboratory, in which internucleotidic phosphate groups have been replaced by N-(p-toluenesulfonyl)-phosphoramidate (Tsp) groups. These oligomers can form complementary duplexes with…

Building fundamental mechanistic insights into factors leading to productive cell uptake and target inhibition by antisense oligonucleotides

Emily Linnane and Sarah Ross

AstraZeneca R&D, Oncology iMed, Hodgkin Building, Chesterford Research Park, Saffron Walden, CB10 1XL

Significant progress has been made in the development of antisense oligonucleotides (ASO) as therapeutic agents across a number of clinical indications. However limited information in the field of antisense trafficking means that this technology cannot be exploited to its full potential. There is still much to elucidate regarding the pathways regulating trafficking of unformulated (or delivery free) ASOs leading to robust target knockdown within cells (a process termed productive uptake), including what factors may impact mode of uptake and trafficking…

Protein Driven Aptamer Toehold Switches Integrated into DNA Origami Nanostructures

Simon Chi-Chin Shiu1, Marco SL Tang1, Roderick M Dirkzwager1, Shaolin Liang1, Andrew B Kinghorn1, Yee-Wai Cheung,1 Lewis A Fraser,1 Maia Godonoga,2 Jonathan G Heddle3 and Julian A Tanner1

1School of Biomedical Sciences, The University of Hong Kong, Laboratory Block, 21 Sassoon Road, Hong Kong
3Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsu-cho, Shinjuku, Tokyo 162-8480, Japan
2Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30–387, Krakow, Poland

DNA can be programmed to fold into a wide variety of nanoscale objects for applications including drug delivery, cell imaging and diagnostics. DNA origami is an established DNA nanostructure but new approaches that can trigger conformational change in origami dynamics are needed. In particular there are few ways by which proteins can trigger DNA nanostructure responses. Oligonucleotide aptamers provide a mechanism by which DNA nanostructures can be programmed to respond to a protein binding event. Here, we show how an aptamer…

The therapeutic potential of aptamer conjugated deoxyoligonucleotides as antimicrobial drugs

Jennifer P Soundy and Darren J Day

Centre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington, Kelburn, Wellington, New Zealand

G4-decoy oligonucleotides: lipid nanoparticle delivery and bioactivity in pancreatic cancer cells

Susanna Cogoi2, Ulla Jakobsen1,3, Erik B Pedersen1, Luigi E Xodo2 and Stefan Vogel1

1Nucleic Acid Center, Institute of Physics and Chemistry, University of Southern Denmark, DK-5230 Odense M, Denmark
2Department of Medical and Biological Sciences, P. le Kolbe 4, 33100 Udine, Italy
3PET & Cyclotron Unit, Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark

KRAS is mutated in >90% of pancreatic ductal adenocarcinomas (PDAC). As its inactivation leads to tumour regression, mutant KRAS is considered an attractive target for anticancer drugs. In this study we report a new delivery strategy for a G4-decoy oligonucleotide that sequesters MAZ (myc-associated zinc-finger), a transcription factor essential for KRAS transcription. Delivery is based on the use of liposomes functionalized with lipid-modified G4-decoy oligonucleotides and a lipid-modified cell penetrating TAT peptide. The potency of the strategy in pancreatic cancer cells…